Treatment for the progression of Parkinson's disease

Lancet Neurology

Volumn 4, Issue 4, 2005, Pages 206-

  Calne, Donald ^a   Schulzer, Michael ^a   Mak, Edwin ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ARTIFACT; BEHAVIOR; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; HUMAN; IMAGE ANALYSIS; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; SHORT SURVEY; STATISTICAL SIGNIFICANCE; SYMPTOM; VALIDATION PROCESS;

EID: 15044364587     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(05)70026-0     Document Type: Letter

References (7)

1. S Fahn, D Oakes, I Shoulson Levodopa and the progression of Parkinson's disease N Engl J Med 351 2004 2498 2508
2. K Marek, I Seibyl, I Shoulson Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 287 2002 1653 51
3. AL Whone, RL Watts, AJ Stoessl Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 54 2003 93 101
4. DB Calne, ASD Spiers, GM Stern, DR Laurence, P Armitage L-dopa in idiopathic parkinsonism Lancet 2 1969 973 976
5. M Guttman, D Stewart, D Hussey, A Wilson, S Houle, S Kish Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD Neurology 56 2001 1559 1564
6. S Senn, F Harrell On wisdom after the event J Clin Epidemiol 50 1997 749 751
7. Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch Neurol 61 2004 561 566